Finoriq research workspace
ADC Therapeutics SA (ADCT) SEC Filings & Filing Highlights
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland. Review ADCT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
- Company
- ADC Therapeutics SA (ADCT)
- Ticker
- ADCT
- Market Cap
- $160.3M
- Latest Price
- $1.26
- Industry
- Biotech & Pharma
ADC Therapeutics SA (ADCT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ADC Therapeutics SA (ADCT).
| Event | Form | Date |
|---|---|---|
| On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advic...On June 30, 2026, the Board of Directors of ADC Therapeutics SA (the “Company”), with the advice of its independent compensation consultant... | 8-K5.02 | 2026-07-02 |
| ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities a...ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities | 8-K8.01 | 2026-06-24 |
| ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities a...ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities | 8-K7.01 | 2026-06-24 |
| ADC Therapeutics SA: Corporate updateOn June 3, 2026, the Company announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirin... | 8-K8.01 | 2026-06-03 |
| In connection with the events described under Item 8.01 below, ADC Therapeutics SA issued a pre...In connection with the events described under Item 8.01 below, ADC Therapeutics SA (the “Company”) issued a press release and made availabl... | 8-K7.01 | 2026-06-03 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.